Two major obstacles persist in the fight against cancer: its heterogeneity and its ability to adapt. Cancers originating from a specific organ system can have various variants, each defined by unique patterns of cellular abnormalities that drive their oncogenic properties. This heterogeneity creates challenges not only in understanding the molecular mechanisms behind the cancer but also in developing effective treatments. Furthermore, even when effective treatments are identified, cancer often adapts and becomes resistant to these therapies, rendering many initially promising treatments ineffective. These challenges highlight the pressing need for new and more advanced cancer treatments that are specifically tailored to the individual cancer strain of each patient.